Dihydralazine sulfate | CAS# 7327-87-9 (sulfate) | antihypertensive agent

MedKoo Cat#: 414331 | Name: Dihydralazine sulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dihydralazine sulfate is an antihypertensive agent with actions and uses similar to those of HYDRALAZINE.

Chemical Structure

Dihydralazine sulfate

CAS#7327-87-9 (sulfate)

Theoretical Analysis

MedKoo Cat#: 414331

Name: Dihydralazine sulfate

CAS#: 7327-87-9 (sulfate)

Chemical Formula: C8H12N6O4S

Exact Mass:

Molecular Weight: 288.28

Elemental Analysis: C, 33.33; H, 4.20; N, 29.15; O, 22.20; S, 11.12

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 636.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

7327-87-9 (sulfate) 484-23-1 (free base)

Synonym

Dihydralazine sulfate; CCRIS5386; CCRIS-5386; CCRIS 5386

IUPAC/Chemical Name

1,4-Dihydrazinophthalazine hydrogen sulfate

InChi Key

BWHAMWGGORIDBK-UHFFFAOYSA-N

InChi Code

InChI=1S/C8H10N6.H2O4S/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;1-5(2,3)4/h1-4H,9-10H2,(H,11,13)(H,12,14);(H2,1,2,3,4)

SMILES Code

NNC1=NN=C(NN)C2=C1C=CC=C2.O=S(O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 288.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Boulebd H, Khodja IA, Bay MV, Hoa NT, Mechler A, Vo QV. Thermodynamic and Kinetic Studies of the Radical Scavenging Behavior of Hydralazine and Dihydralazine: Theoretical Insights. J Phys Chem B. 2020 May 21;124(20):4123-4131. doi: 10.1021/acs.jpcb.0c02439. Epub 2020 May 6. PMID: 32315525. 2: Gumieniczek A, Galeza J, Mroczek T, Wojtanowski K, Lipska K, Pietras R. Kinetics and Characterization of Degradation Products of Dihydralazine and Hydrochlorothiazide in Binary Mixture by HPLC-UV, LC-DAD and LC-MS Methods. Chromatographia. 2018;81(8):1147-1162. doi: 10.1007/s10337-018-3555-8. Epub 2018 Jun 25. PMID: 30220731; PMCID: PMC6132553. 3: Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018 Sep;84(9):1906-1916. doi: 10.1111/bcp.13649. Epub 2018 Jul 8. PMID: 29974489; PMCID: PMC6089822. 4: Reinen J, Smit M, Wenker M. Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750. doi: 10.1007/s13318-018-0485-7. PMID: 29785610. 5: Han S, Fan Z, Chen X, Wu Y, Wang J. Determination of dihydralazine based on chemiluminescence resonance energy transfer of hollow carbon nanodots. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Aug 5;183:103-108. doi: 10.1016/j.saa.2017.04.009. Epub 2017 Apr 20. PMID: 28441537. 6: Wyczalkowska-Tomasik A, Bartlomiejczyk I, Wirkowska A, Koperski L, Gornicka B, Paczek L. The Blocking on the Cathepsin B and Fibronectin Accumulation in Kidney Glomeruli of Diabetic Rats. Int J Endocrinol. 2015;2015:812825. doi: 10.1155/2015/812825. Epub 2015 May 18. PMID: 26089895; PMCID: PMC4452094. 7: Bijvank SW, Visser W, Duvekot JJ, Steegers EA, Edens MA, Roofthooft DW, Vulto AG, Hanff LM. Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015 Jun;189:106-11. doi: 10.1016/j.ejogrb.2015.02.002. Epub 2015 Mar 10. PMID: 25892082. 8: Niehoff MO, Niggemann B, Sternberg J, Jenkins A, Holbrook M. Measurement of hyper- and hypotension during repeated dose toxicity studies in either freely moving or physically restrained cynomolgus monkeys. J Pharmacol Toxicol Methods. 2014 Nov-Dec;70(3):268-75. doi: 10.1016/j.vascn.2014.09.004. Epub 2014 Sep 16. PMID: 25219539. 9: Chen J, Zhao X, Wang H, Chen Y, Wang W, Zhou W, Wang X, Tang J, Zhao Y, Lu X, Chen S, Wang L, Shen C, Yang S. Common variants in TGFBR2 and miR-518 genes are associated with hypertension in the Chinese population. Am J Hypertens. 2014 Oct;27(10):1268-76. doi: 10.1093/ajh/hpu047. Epub 2014 Mar 31. PMID: 24687999; PMCID: PMC4815702. 10: Gut N, Piecha G, Aldebssi F, Schaefer S, Bekeredjian R, Schirmacher P, Ritz E, Gross-Weissmann ML. Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function. Am J Nephrol. 2013;38(2):124-35. doi: 10.1159/000353106. Epub 2013 Jul 30. PMID: 23920063. 11: Kryczka K, Dzielińska Z, Przybylski A, Szczudlik J, Dangel J, Konka M, Czajkowski K, Różański J, Bilińska ZT, Demkow M. Therapeutic challenges and management of heart failure during pregnancy (part I). Med Sci Monit. 2012 May;18(5):CQ5-7. doi: 10.12659/msm.882716. PMID: 22534703. 12: Schwarte LA, Schwartges I, Scheeren TW, Schober P, Picker O. The differential effects of recombinant brain natriuretic peptide, nitroglycerine and dihydralazine on systemic oxygen delivery and gastric mucosal microvascular oxygenation in dogs. Anaesthesia. 2012 May;67(5):501-7. doi: 10.1111/j.1365-2044.2011.07047.x. Epub 2012 Feb 21. PMID: 22352680. 13: Wu Y, Hu Y, Tang X, He L, Ren T, Tao Q, Qin X, Sun N, Wang H, Cao W, Wu T, Zhan S, Wang J, Chen W, Li L. Long-term efficacy and tolerability of a fixed- dose combination of antihypertensive agents: an open-label surveillance study in China. Clin Drug Investig. 2011 Nov 1;31(11):769-77. doi: 10.1007/BF03256917. PMID: 21671689. 14: Tyralla K, Adamczak M, Benz K, Campean V, Gross ML, Hilgers KF, Ritz E, Amann K. High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy. PLoS One. 2011 Jan 27;6(1):e15287. doi: 10.1371/journal.pone.0015287. PMID: 21298056; PMCID: PMC3029304. 15: Serreau R; Collége national des gynécologues et obstétriciens; Société française de médecine périnatale; Société française de néonatalogie; Société française de anesthésie et de réanimation. Médicaments utilisés dans la prise en charge de la prééclampsie. Pharmacologie et risques foetaux [Drugs during preeclampsia. Fetal risks and pharmacology]. Ann Fr Anesth Reanim. 2010 Apr;29(4):e37-46. French. doi: 10.1016/j.annfar.2010.02.016. Epub 2010 Mar 27. PMID: 20347563. 16: Njoku DB. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. Expert Opin Drug Metab Toxicol. 2010 May;6(5):519-31. doi: 10.1517/17425251003601979. PMID: 20166853; PMCID: PMC3656827. 17: Yang C, Zhang Z, Wang J. Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system. Spectrochim Acta A Mol Biomol Spectrosc. 2010 Jan;75(1):77-82. doi: 10.1016/j.saa.2009.09.044. Epub 2009 Oct 6. PMID: 19910243. 18: Wang B, Zhou SF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. doi: 10.2174/092986709789378198. PMID: 19754423. 19: Seck K, Fischer T. Empfehlungen zur Diagnostik und Behandlung der Präeklampsie im internationalen Vergleich: Was ist neu? [Diagnosis and treatment of preeclampsia: overview of international recommendations]. Z Geburtshilfe Neonatol. 2009 Jun;213(3):106-12. German. doi: 10.1055/s-0029-1224157. Epub 2009 Jun 17. PMID: 19536711. 20: Adcock JL, Francis PS, Barnett NW. Emitting species in chemiluminescence reactions with acidic potassium permanganate: a re-evaluation based on new spectroscopic evidence. J Fluoresc. 2009 Sep;19(5):867-74. doi: 10.1007/s10895-009-0485-8. Epub 2009 Apr 8. PMID: 19353245.